Product Description
Mechanisms of Action: Digitoxigenin Analogue
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Windtree
Company Location:
Company CEO:
Additonal Commercial Interests: Lee's Limited
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Hypertension|Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CVT-CV-001 | P2 |
Completed |
Hypertension |
2018-02-08 |
24% |
| PEARL-HT | P2 |
Completed |
Hypertension |
2013-01-09 |
|
| PST 2238-DM-10-001 | P2 |
Unknown status |
Hypertension |
2012-07-01 |
|
| Rostafuroxin (PST2238) in Type 2 diabetes | P2 |
Terminated |
Type 2 Diabetes |
2012-03-21 |